{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T16:15:05Z","timestamp":1726848905024},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1097\/inf.0000000000001278","type":"journal-article","created":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T20:05:21Z","timestamp":1466107521000},"page":"1242-1246","source":"Crossref","is-referenced-by-count":2,"title":["Do Dose Numbers Matter?"],"prefix":"10.1097","volume":"35","author":[{"given":"Julie A.","family":"Bettinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otto G.","family":"Vanderkooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Scheifele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Schryvers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaston","family":"De Serres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joenel","family":"Alcantara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-19-20210202","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.vaccine.2003.09.022","article-title":"Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease.","volume":"22","author":"De Wals","year":"2004","journal-title":"Vaccine"},{"key":"R4-19-20210202","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1016\/j.vaccine.2006.02.010","article-title":"Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation.","volume":"24","author":"De Wals","year":"2006","journal-title":"Vaccine"},{"key":"R5-19-20210202","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/INF.0b013e3181f728fd","article-title":"Persistence of immunity following a booster dose of Haemophilus influenzae type B-meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.","volume":"30","author":"Khatami","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R6-19-20210202","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/CVI.00384-09","article-title":"Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine.","volume":"17","author":"Borrow","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R7-19-20210202","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","article-title":"Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.","volume":"24","author":"Snape","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R8-19-20210202","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"R9-19-20210202","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"R10-19-20210202","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1016\/j.vaccine.2012.04.034","article-title":"Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis.","volume":"30","author":"Bettinger","year":"2012","journal-title":"Vaccine"},{"key":"R11-19-20210202","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"R12-19-20210202","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England.","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"R13-19-20210202","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity.","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"R14-19-20210202","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/CVI.00009-07","article-title":"Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation.","volume":"14","author":"Fusco","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"R15-19-20210202","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1128\/IAI.69.4.2378-2382.2001","article-title":"Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.","volume":"69","author":"Richmond","year":"2001","journal-title":"Infect Immun"},{"key":"R16-19-20210202","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14760584.8.3.265","article-title":"Prevention of meningococcal serogroup C disease by NeisVac-C.","volume":"8","author":"Borrow","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"R17-19-20210202","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/INF.0b013e31827e22e3","article-title":"A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.","volume":"32","author":"Vesikari","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R18-19-20210202","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/INF.0b013e31816b4561","article-title":"Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13\u201314 months of age with antibody persistence up to 31 months of age.","volume":"27","author":"Tejedor","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R23-19-20210202","doi-asserted-by":"crossref","first-page":"h1554","DOI":"10.1136\/bmj.h1554","article-title":"Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.","volume":"350","author":"Pace","year":"2015","journal-title":"BMJ"},{"key":"R24-19-20210202","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1016\/j.vaccine.2013.04.070","article-title":"Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C\u00ae) in infants.","volume":"31","author":"Poellabauer","year":"2013","journal-title":"Vaccine"},{"key":"R25-19-20210202","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1128\/IAI.70.9.4946-4954.2002","article-title":"Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection.","volume":"70","author":"Burrage","year":"2002","journal-title":"Infect Immun"},{"key":"R26-19-20210202","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1128\/IAI.71.10.5549-5555.2003","article-title":"Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom.","volume":"71","author":"Borrow","year":"2003","journal-title":"Infect Immun"},{"key":"R27-19-20210202","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.vaccine.2014.12.018","article-title":"Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule.","volume":"33","author":"Ladhani","year":"2015","journal-title":"Vaccine"},{"key":"R28-19-20210202","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/317646","article-title":"Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.","volume":"183","author":"Richmond","year":"2001","journal-title":"J Infect Dis"},{"key":"R29-19-20210202","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/INF.0b013e3181b9a831","article-title":"A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months.","volume":"29","author":"Diez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R30-19-20210202","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/INF.0b013e3181d9e653","article-title":"Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life.","volume":"29","author":"Diez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R31-19-20210202","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.vaccine.2005.07.060","article-title":"Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP\/Hib vaccine.","volume":"24","author":"Southern","year":"2006","journal-title":"Vaccine"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000001278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:11:54Z","timestamp":1620954714000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201611000-00019"}},"subtitle":["Evaluation of Differing Infant and Toddler Meningococcal C Conjugate Vaccine Programs in Canadian Children"],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001278","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}